Vasculitis Research Pipeline

According to NIH funding data, a substantial amount of public research funding has been directed toward vasculitis in the United States. However, the direction of that funding has been falling year on year, which may mean that some of the foundational scientific questions are considered answered, or that research priorities are shifting elsewhere. For patients, this is worth watching, as sustained funding is often what drives new treatments from the laboratory toward clinical use.

Registry data shows that trials are active at both early and late stages of development, which is an encouraging sign for the overall progress of vasculitis research. Early stage trials suggest researchers are still exploring new approaches and testing safety, while late stage activity points to treatments that have already cleared significant scientific hurdles and are being assessed for broader use. This mix of Phase 1 through to Phase 3 activity suggests the field is not stalled but is progressing along multiple fronts at once.

For Australian patients, the picture is less clear at this stage. No TGA approval has been recorded in the available data for vasculitis treatments under review, and no PBS listing status has been recorded, meaning that newer treatments being studied in trials may not yet be accessible or subsidised locally. No patent activity has been recorded either, which can sometimes indicate that commercial development is still at an early or uncertain stage. Australian patients are encouraged to speak with their specialist about what options are currently available to them, including whether participation in a clinical trial might be appropriate. This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.